Eyenovia announces FDA acceptance of MicroStat IND application for mydriasis
Eyenovia announced the FDA has accepted the Company’s Investigational New Drug application to initiate Phase III trials of MicroStat for diagnostic mydriasis. MicroStat is a first in class fixed-combination of phenylephrine and tropicamide for in office mydriasis (pupil dilation). November 13, 2018